Provided by Tiger Fintech (Singapore) Pte. Ltd.

Vir Biotechnology, Inc.

4.41
-0.1750-3.82%
Volume:388.68K
Turnover:1.73M
Market Cap:611.93M
PE:-1.10
High:4.62
Open:4.58
Low:4.38
Close:4.58
52wk High:14.45
52wk Low:4.16
Shares:138.92M
Float Shares:94.55M
Volume Ratio:0.96
T/O Rate:0.41%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.0061
EPS(LYR):-3.8310
ROE:-46.22%
ROA:-24.73%
PB:0.65
PE(LYR):-1.15

Loading ...

Raymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR)

TIPRANKS
·
Aug 07

Stock Track | Vir Biotechnology Plummets 5.71% as Q2 Revenue Misses Estimates, Falling 61% Year-over-Year

Stock Track
·
Aug 07

Earnings Flash: (VIR) Vir Biotechnology Q2 Loss $0.80 Vs. FactSet Est. $0.72 Loss

MT Newswires Live
·
Aug 07

Stock Track | Vir Biotechnology Plunges 5.12% After-Hours on Q2 Earnings Miss

Stock Track
·
Aug 07

Stock Track | Vir Biotechnology Plunges 5.12% After Hours on Disappointing Q2 Earnings

Stock Track
·
Aug 07

Vir Biotechnology Q2 EPS $(0.80) Misses $(0.76) Estimate, Sales $1.21M Miss $2.38M Estimate

Benzinga
·
Aug 07

BRIEF-Vir Biotechnology Successfully Initiates All Trials In Eclipse Registrational Program

Reuters
·
Aug 06

Stock Track | Vir Biotechnology Soars 8% Pre-market on Successful Initiation of Chronic Hepatitis Delta Trials

Stock Track
·
Aug 06

Vir Biotechnology Successfully Initiates All Trials in Eclipse Registrational Program for Chronic Hepatitis Delta

THOMSON REUTERS
·
Aug 06

Vir Biotechnology Initiates ECLIPSE 3 Trial in Registrational Program for Chronic Hepatitis Delta

Reuters
·
Aug 06

Director Vicki L. Sato Reports Disposal of Common Shares in Vir Biotechnology Inc

Reuters
·
Aug 05

Vir Biotechnology Launches Phase 3 ECLIPSE 2 Trial for Chronic Hepatitis Delta Treatment

Reuters
·
Jul 31

Vir Biotechnology Begins Phase 1 Trial for VIR-5525

TIPRANKS
·
Jul 27

Vir Biotechnology Announces Launch of Phase 1 Clinical Trial for EGFR-Targeting T-Cell Engager VIR-5525 in Solid Tumors

Reuters
·
Jul 24

Vir Biotechnology Announces First Patient Dosed in Phase 1 Clinical Trial of Egfr-Targeting Pro-Xten™ Dual-Masked T-Cell Engager Vir-5525 for the Treatment of Solid Tumors

THOMSON REUTERS
·
Jul 24

Vir Biotechnology Inc. to Report Second Quarter 2025 Financial Results

Reuters
·
Jul 23

Mark Eisner, EVP and Chief Medical Officer, Reports Disposal of Common Shares of Vir Biotechnology Inc

Reuters
·
Jul 18

Raymond James Initiates Vir Biotechnology at Outperform With $12 Price Target

MT Newswires Live
·
Jul 11

Director Vicki L. Sato Reports Disposal of Common Shares in Vir Biotechnology Inc

Reuters
·
Jul 03

Trump Says Pharma Tariffs Coming Very Soon

Reuters
·
Jun 17